Applied Genetic Technologies Corp.
Applied Genetic Technologies Corp. is listed today as Applied Genetic Technologies Corporation: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2012 | $9 M | No. 2 | $2 to $10 million | equity | SEC | |
| Nov 2003 | $34 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Applied Genetic Technologies Corp. chose not to state its revenue in its newest notice of a funding round (Nov 2012).
SEC Form D · Nov 2012
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2012
That is all the official record says: Applied Genetic Technologies Corp. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Applied Genetic Technologies Corp. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alta Partners Management VIII, LLC | Fund or asset manager | not stated | not stated | Held Series B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Alta Partners VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| GSK PLC | Fund or asset manager | not stated | not stated | Held Series B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Interwest Investors Q VIII LP | Fund or asset manager | not stated | not stated | Held Series A-1, B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Interwest Investors VIII L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| InterWest Management Partners VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A-1, B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| Interwest Partners VIII LP | Fund or asset manager | not stated | not stated | Held Series A-1, B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
| MedImmune Ventures, Inc. | Venture capital | not stated | not stated | Held Series A-1A, B-1, B-2 and B-3 preferred stock, 10% owner (Form 3, 2014) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Susan B Washer | Executive officer | Nov 2012 |
| Arnold B Oronsky | Director | Nov 2012 |
| Edward B Hurwitz | Director | Nov 2012 |
| James B Rosen | Director | Nov 2012 |
| Kent B Gossett | Director | Nov 2012 |
| Samuel B Wu | Director | Nov 2012 |
| Scott B Koenig | Director | Nov 2012 |
| Susan B Washer | Director | Nov 2012 |
| Arnold Oronsky | Director | Jul 2009 |
| Frank Top | Director | Jul 2009 |
| Garheng Kong | Director | Jul 2009 |
| Nicholas Muzyczka | Director | Jul 2009 |
| Scott Koenig | Director | Jul 2009 |
About
Biotechnology company.